Elsevier

Life Sciences

Volume 74, Issues 2–3, 5 December 2003, Pages 143-153
Life Sciences

EP2 and EP4 prostanoid receptor signaling

https://doi.org/10.1016/j.lfs.2003.09.031Get rights and content

Abstract

The EP2 and EP4 prostanoid receptors are two of the four subtypes of receptors for prostaglandin E2 (PGE2). They are in the family of G-protein coupled receptors and both receptors were initially characterized as coupling to Gs and increasing intracellular cAMP formation. Recently, however, we have shown that both receptors can stimulate T-cell factor (Tcf) mediated transcriptional activity. The EP2 receptor does this primarily through cAMP-dependent protein kinase (PKA), whereas the EP4 utilizes phosphatidylinositol 3-kinase (PI3K) as well as PKA. In addition, we have shown that the EP4 receptor, but not the EP2, can activate the extracellular signal-regulated kinases (ERKs) 1 and 2 by way of PI3K leading to the induction of early growth response factor-1 (EGR-1), a transcription factor traditionally associated with wound healing. This induction of EGR-1 expression has significant implications concerning the potential role of PGE2 in cancer and inflammatory disorders.

Introduction

Prostaglandin E2 (PGE2) is one of five major products produced by the initial actions of the cyclooxygenases on arachidonic acid. The other four products are PGF, PGD2, PGI2 and thromboxane A2 (TxA2). Collectively these products are referred to as prostanoids and the receptors that mediate their actions are known as prostanoid receptors. There are two cyclooxygenases, abbreviated COX-1 and COX-2, that convert arachidonic acid to PGH2 (Smith et al., 2000). COX-1 is constitutively expressed in most tissues, although the level of its expression can be affected by a number of factors. COX-2 expression is more tightly regulated and under most normal physiological conditions it is not expressed. However, under a variety of pathophysiological conditions its expression can be rapidly induced. PGH2 is the initial metabolite produced by both enzymes, which is then converted to the final products through the actions of specific synthases. For example, PGE2 synthase (PGES) catalyzes the conversion of PGH2 to PGE2. There are three forms of this enzyme that are uniquely different from one another (Kamei et al., 2003). One is found in the cytosol and is referred to as cPGES. The other two are found in microsomal fractions and are abbreviated mPGES1 and mPGES2. The expression of mPGES1 is inducible and appears to be correlated with the expression of COX-2 (Murakami et al., 2000).

The prostanoid receptors are in the superfamily of G-protein coupled receptors (GPCR). These receptors were first defined pharmacologically as EP, FP, DP, IP and TP, which referred to the endogenous ligands that activated these receptors, i.e. PGE2, PGF, PGD2, PGI2 and TxA2 (Coleman et al., 1994b). There is considerable heterogeneity of the prostanoid receptors due to the presence of genes encoding separate subtypes and due to alternative mRNA splicing. For the EP receptors there are four subtypes that are the products of separate genes (EP1, EP2, EP3 and EP4). Additionally there are two alternative splice variants of the EP1 receptor and eight variants of the EP3 receptor.

Section snippets

Cloning of the EP receptors

Initially there was some confusion regarding the identity of the cloned EP2 and EP4 receptors because it was previously thought that there were only three EP receptors and only one, the EP2, was thought to be coupled to the stimulation of adenylyl cyclase. The remaining EP1 and EP3 receptors were defined as coupling, respectively, to either the activation of phospholipase C or the inhibition of adenylyl cyclase. The first two EP receptors to be cloned were the EP3 (Sugimoto et al., 1992) and

Structure and regulation of the EP2 and EP4 receptors

Fig. 1 shows an alignment of the primary amino acid sequences of the human EP2 and EP4 receptors and their amino acid identity. Although sharing obvious similarities in their pharmacology and functional coupling, they only share approximately 38% identity in their transmembrane domains, which is not appreciably different from the amino acid identity they share with the EP1 (37%) and EP3 (34%) receptors. In fact, phylogenetic analysis shows that the EP2 receptor is actually more closely related

Second messenger signaling of the EP2 and EP4 receptors

As stated previously, with respect to second messenger signaling, the distinguishing feature of the EP2 and EP4 prostanoid receptors was their ability to stimulate intracellular cAMP formation. This was demonstrated following the cloning of both of these receptors and their transient expression in COS cells. For the EP4 receptor stimulation with PGE2 produced an ~8 fold increase in cAMP formation over untransfected COS cells (Honda et al., 1993); while for the EP2 receptor, PGE2 stimulated cAMP

Knockout studies of the EP2 and EP4 receptors

The use of gene knockout studies to create animals lacking the various prostanoid receptors has contributed significantly to our understanding of their potential physiology and pathophysiology (Kobayashi and Narumiya, 2002). This is especially true of the EP2 and EP4 receptors since prior the cloning of these receptors it was thought that all the effects of PGE2 involving the activation of adenylyl cyclase were through one receptor subtype. Table 1, Table 2 list studies in which the use of

Acknowledgements

I would like to thank Dr. Hiromichi Fujino for his contributions to this work and Sambhitab Salvi for his help with Fig. 1. The following organizations for their support: the National Eye Institute (EY11291), Allergan Inc., and the Arizona Disease Control Research Commission.

References (43)

  • S. Shinomiya et al.

    Regulation of TNFα and interleukin-10 production by prostaglandins, I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists

    Biochem. Pharmacol.

    (2001)
  • B.A. Stillman et al.

    A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding

    Eur. J. Pharmacol.

    (1998)
  • Y. Sugimoto et al.

    Cloning and expression of a cDNA for mouse prostaglandin E Receptor EP3 subtype

    J. Biol. Chem.

    (1992)
  • K. Takayama et al.

    Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor

    J. Biol. Chem.

    (2002)
  • H. Toh et al.

    Molecular evolution of receptors for eicosanoids

    FEBS Letters

    (1995)
  • A. Watabe et al.

    Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor

    J. Biol. Chem.

    (1993)
  • Y. Araki et al.

    Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways

    Cancer Res.

    (2003)
  • K.M. Cadigan et al.

    Wnt signaling: a common theme in animal development

    Genes Dev.

    (1997)
  • R.A. Coleman et al.

    VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes

    Pharmacol. Rev.

    (1994)
  • S. Desai et al.

    Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration

    Mol. Pharmacol.

    (2000)
  • Fujisawa Pharm. Co., 2000. Oxazole compounds as prostaglandin E2 agonists or antagonists. Patent...
  • Cited by (390)

    • Sex differences in the brain: Focus on developmental mechanisms

      2023, Principles of Gender-Specific Medicine: Sex and Gender-Specific Biology in the Postgenomic Era
    View all citing articles on Scopus
    View full text